ZS Pharma Company Profile (NASDAQ:ZSPH)

About ZS Pharma (NASDAQ:ZSPH)

ZS Pharma logoZS Pharma, Inc. is a biopharmaceutical company focused on the development and commercialization of non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. The Company's zirconium silicate technology allows it to create selective ion traps that can reduce toxic levels of specific electrolytes without disturbing the balance of other electrolytes. The Company has completed Phase III development of its product candidate, sodium zirconium cyclosilicate (ZS-9), for the treatment of hyperkalemia, a life-threatening condition in which elevated levels of potassium increase the risk of muscle dysfunction, including cardiac arrhythmias and sudden cardiac death. The Company has completed three clinical studies with ZS-9 for patients with hyperkalemia, including patients with chronic kidney disease (CKD), heart failure (HF), diabetes and those on renin-angiotensin aldosterone system (RAAS) inhibitor therapy.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ZSPH
  • CUSIP: N/A
  • Web: www.zspharma.com
Average Prices:
  • 50 Day Moving Avg: $85.57
  • 200 Day Moving Avg: $66.48
  • 52 Week Range: $37.52 - $91.24
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.71
  • P/E Growth: 0.00
Profitability:
  • Return on Equity: -66.24%
  • Return on Assets: -58.88%
Misc:
  • Average Volume: 918,928 shs.
 
Frequently Asked Questions for ZS Pharma (NASDAQ:ZSPH)

What is ZS Pharma's stock symbol?

ZS Pharma trades on the NASDAQ under the ticker symbol "ZSPH."

How were ZS Pharma's earnings last quarter?

ZS Pharma Inc (NASDAQ:ZSPH) issued its quarterly earnings results on Monday, November, 9th. The company reported ($0.41) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.04) by $0.63. View ZS Pharma's Earnings History.

Who are some of ZS Pharma's key competitors?

How do I buy ZS Pharma stock?

Shares of ZS Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ZS Pharma's stock price today?

One share of ZS Pharma stock can currently be purchased for approximately $89.98.


MarketBeat Community Rating for ZS Pharma (NASDAQ ZSPH)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  90
MarketBeat's community ratings are surveys of what our community members think about ZS Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ZS Pharma (NASDAQ:ZSPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ZS Pharma (NASDAQ:ZSPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/18/2015Citigroup Inc.DowngradeBuy -> Neutral$90.00N/AView Rating Details
11/9/2015J P Morgan Chase & CoDowngradeOverweight -> Neutral$75.00 -> $90.00N/AView Rating Details
11/9/2015Morgan StanleyDowngradeOverweight -> Equal Weight$79.00 -> $90.00N/AView Rating Details
11/9/2015Credit Suisse GroupDowngradeOutperform -> Neutral$67.00 -> $90.00N/AView Rating Details
11/6/2015William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
9/11/2015BMO Capital MarketsReiterated RatingBuy$70.00 -> $83.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for ZS Pharma (NASDAQ:ZSPH)
Earnings by Quarter for ZS Pharma (NASDAQ:ZSPH)
Earnings History by Quarter for ZS Pharma (NASDAQ ZSPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2015Q315($1.04)($0.41)ViewN/AView Earnings Details
8/6/2015($0.90)($1.30)ViewN/AView Earnings Details
5/11/2015Q115($0.86)($1.05)ViewN/AView Earnings Details
3/13/2015Q414($0.75)($0.98)ViewN/AView Earnings Details
11/10/2014Q314($0.74)($0.81)ViewN/AView Earnings Details
8/14/2014Q214($0.66)($4.72)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ZS Pharma (NASDAQ:ZSPH)
Current Year EPS Consensus Estimate: $-4.68 EPS
Next Year EPS Consensus Estimate: $-5.08 EPS

Dividends

Dividend History for ZS Pharma (NASDAQ:ZSPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ZS Pharma (NASDAQ:ZSPH)
Insider Trades by Quarter for ZS Pharma (NASDAQ:ZSPH)
Insider Trades by Quarter for ZS Pharma (NASDAQ:ZSPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/21/2015Todd A. CreechCFOSell70,000$49.84$3,488,800.00View SEC Filing  
6/8/2015Alta Partners Viii, L.P.Major ShareholderSell175,427$57.86$10,150,206.22View SEC Filing  
6/4/2015Alta Partners Viii, L.P.Major ShareholderSell111,597$57.30$6,394,508.10View SEC Filing  
6/2/2015Alta Partners Viii, L.P.Major ShareholderSell296,423$58.00$17,192,534.00View SEC Filing  
6/23/2014A/S NovoInsiderBuy275,000$18.00$4,950,000.00View SEC Filing  
6/23/2014Guy P NohraDirectorBuy200,000$18.00$3,600,000.00View SEC Filing  
6/23/2014Park Bioventures Lp DevonMajor ShareholderBuy160,000$18.00$2,880,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ZS Pharma (NASDAQ:ZSPH)
Latest Headlines for ZS Pharma (NASDAQ:ZSPH)
Source:
DateHeadline
americanbankingnews.com logoZS Pharma (ZSPH) Receiving Somewhat Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 20 at 9:17 AM
uk.finance.yahoo.com logoAstraZeneca receives fresh blow to potassium drug
uk.finance.yahoo.com - March 17 at 5:45 AM
uk.finance.yahoo.com logoAstraZeneca receives FDA setback for high potassium drug
uk.finance.yahoo.com - March 17 at 5:45 AM
thestreet.com logoAstraZeneca Gets 'Complete Response Letter' From FDA on Hyperkalaemia Treatment
www.thestreet.com - March 17 at 5:45 AM
seekingalpha.com logoWhat To Do With Your Relypsa Winnings - Seeking Alpha
seekingalpha.com - July 22 at 8:14 PM
fool.com logoShares Of Relypsa Inc. Are Surging Again -- Here's Why
www.fool.com - May 27 at 11:42 AM
bloomberg.com logoAstraZeneca's Good Deal Turns Bad
www.bloomberg.com - May 27 at 11:40 AM
finance.yahoo.com logoAstraZeneca Remains Committed To Development Of ZS-9 Despite Letter From FDA
finance.yahoo.com - May 27 at 7:47 AM
uk.finance.yahoo.com logoQuestor share tip: AstraZeneca faces Crestor crunch in year ahead
uk.finance.yahoo.com - February 5 at 3:59 AM
finance.yahoo.com logoActelion says selexipag to enter U.S. market in January
finance.yahoo.com - December 22 at 1:32 AM
moodys.com logoAstraZeneca PLC -- Moody's downgrades AstraZeneca to A3, stable outlook
www.moodys.com - December 18 at 12:47 PM
biz.yahoo.com logoZS PHARMA, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failur
biz.yahoo.com - December 17 at 5:07 PM
bizjournals.com logoAstraZeneca confirms interest in a possible $5B purchase
www.bizjournals.com - December 14 at 9:30 AM
finance.yahoo.com logoZS PHARMA, INC. Financials
finance.yahoo.com - December 8 at 1:17 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ZS Pharma, Inc. of Commencement of an Investigation In Connection With the Fairness of the Sale of the Company to AstraZeneca PLC -- ZSPH
finance.yahoo.com - November 13 at 12:49 PM

Social

Chart

ZS Pharma (ZSPH) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff